Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Inflammation
Published in: Inflammation 4/2016

01-08-2016 | ORIGINAL ARTICLE

Polyomavirus BK Induces Inflammation via Up-regulation of CXCL10 at Translation Levels in Renal Transplant Patients with Nephropathy

Authors: Ashraf Kariminik, Shahriar Dabiri, Ramin Yaghobi

Published in: Inflammation | Issue 4/2016

Login to get access

Abstract

Polyomavirus BK-associated nephropathy (BKAN) is an important mechanism for renal losing after kidney transplantation. It seems that Polyomavirus BK can induce nephropathy by direct cell lysis and stimulation of the immune system and induction of inflammation. CXCL10 is a pro-inflammatory cytokine which stimulates the migration and activation of immune cells to the infected sites. Therefore, the aim of the current study was to evaluate the messenger RNA (mRNA) and protein levels of CXCL10 in the Polyomavirus BK-infected and Polyomavirus BK-non-infected post renal transplanted nephropathic patients in comparison to healthy controls. In this cross-sectional study, Polyomavirus BK-infected post renal transplanted nephropathic patients, Polyomavirus BK-non-infected post renal transplanted nephropathic patients, and healthy controls were enrolled to evaluate mRNA and protein levels of CXCL10 by real-time PCR and ELISA techniques, respectively. mRNA levels of CXCL10 were not significantly different among participants, while serum levels of CXCL10 were significantly elevated in the Polyomavirus BK-infected patients when compared to non-infected patients as well as controls and in non-infected patients when compared to healthy controls. Due to the results, it seems that Polyomavirus BK may potentially induce renal losing through stimulation of inflammation via increasing translation of CXCL10, as a pro-inflammatory chemokine.
Literature
1.
Yaghobi, R., M., Ramzi, and S. Dehghani. 2009. The role of different risk factors in clinical presentation of hemorrhagic cystitis in hematopoietic stem cell transplant recipients. Transplantation Proceedings, 2009. Elsevier, 2900–2902.
2.
Pakfetrat, M., R. Yaghobi, Z. Salmanpoor, J. Roozbeh, S. Torabinezhad, and S. Kadkhodaei. 2015. Frequency of Polyomavirus BK infection in kidney transplant patients suspected to nephropathy. IJOTM 6(2): 77–84.PubMedPubMedCentral
3.
Padilla-Fernandez, B., J. Bastida-Bermejo, A. Virseda-Rodriguez, J. Labrador-Gomez, D. Caballero-Barrigon, J. Silva-Abuin, J. San Miguel-Izquierdo, and M. Lorenzo-Gomez. 2014. Hemorrhagic cytitis after bone marrow transplantation. Archivos Españoles de Urología 67(2): 167–174.PubMed
4.
Sharma, S.G., V. Nickeleit, L.C. Herlitz, A.K. de Gonzalez, M.B. Stokes, H.K. Singh, G.S. Markowitz, and V.D. D’Agati. 2013. BK polyoma virus nephropathy in the native kidney. Nephrology, Dialysis, Transplantation 28(3): 620–631.CrossRefPubMed
5.
Shakiba, E., R. Yaghobi, and M. Ramzi. 2011. Prevalence of viral infections and hemorrhagic cystitis in hematopoietic stem cell transplant recipients. Experimental and Clinical Transplantation: Official Journal of the Middle East Society for Organ Transplantation 9(6): 405–412.
6.
Broekema, N.M., and M.J. Imperiale. 2012. Efficient propagation of archetype BK and JC polyomaviruses. Virology 422(2): 235–241.CrossRefPubMed
7.
Geramizadeh, B., J. Roozbeh, S.-A. Malek-Hosseini, N. Azarpira, M. Ayatollahi, H. Salahi, M. Aghdaee, and R. Yaghoobi. 2006. Urine cytology as a useful screening method for polyoma virus nephropathy in renal transplant patients: a single-center experience. Transplantation Proceedings 38(9): 2923–2925.CrossRefPubMed
8.
Boldorini, R., S. Allegrini, U. Miglio, A. Paganotti, N. Cocca, M. Zaffaroni, F. Riboni, G. Monga, and R. Viscidi. 2011. Serological evidence of vertical transmission of JC and BK polyomaviruses in humans. Journal of General Virology 92(5): 1044–1050.CrossRefPubMed
9.
Cepeda, E.B., T. Dediulia, J. Fernando, E. Bertran, G. Egea, E. Navarro, and I. Fabregat. 2015. Mechanisms regulating cell membrane localization of the chemokine receptor CXCR4 in human hepatocarcinoma cells. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1853(5): 1205–1218.CrossRef
10.
Jain, V., H.B. Armah, J.E. Tongren, R.M. Ned, N.O. Wilson, S. Crawford, P.K. Joel, M.P. Singh, A.C. Nagpal, A.P. Dash, V. Udhayakumar, N. Singh, and J.K. Stiles. 2008. Plasma IP-10, apoptotic and angiogenic factors associated with fatal cerebral malaria in India. Malaria Journal 7(1): 83. doi:10.​1186/​1475-2875-7-83.CrossRefPubMedPubMedCentral
11.
Lasagni, L., M. Francalanci, F. Annunziato, E. Lazzeri, S. Giannini, L. Cosmi, C. Sagrinati, B. Mazzinghi, C. Orlando, E. Maggi, F. Marra, S. Romagnani, M. Serio, and P. Romagnani. 2003. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. Journal of Experimental Medicine 197(11): 1537–1549. doi:10.​1084/​jem.​20021897.CrossRefPubMedPubMedCentral
12.
Pineda-Tenor, D., J. Berenguer, M.A. Jiménez-Sousa, M. Guzmán-Fulgencio, T. Aldámiz-Echevarria, A. Carrero, M. García-Álvarez, C. Diez, F. Tejerina, and V. Briz. 2014. CXCL9, CXCL10 and CXCL11 polymorphisms are associated with sustained virologic response in HIV/HCV-coinfected patients. Journal of Clinical Virology 61(3): 423–429.CrossRefPubMed
13.
Lazzeri, E., L. Lasagni, M. Serio, S. Romagnani, and P. Romagnani. 2001. Cytokines and chemokines in nephropathies and renal transplant. Giornale Italiano di Nefrologia: Organo Ufficiale Della Societa Italiana di Nefrologia 19(6): 641–649.
14.
Szczuciński, A., and J. Losy. 2011. CCL5, CXCL10 and CXCL11 chemokines in patients with active and stable relapsing-remitting multiple sclerosis. Neuroimmunomodulation 18(1): 67–72.CrossRefPubMed
15.
Antonelli, A., S.M. Ferrari, A. Corrado, E. Ferrannini, and P. Fallahi. 2013. Increase of interferon-γ inducible CXCL9 and CXCL11 serum levels in patients with active Graves’ disease and modulation by methimazole therapy. Thyroid 23(11): 1461–1469.CrossRefPubMed
16.
Hickman, H.D., G.V. Reynoso, B.F. Ngudiankama, S.S. Cush, J. Gibbs, J.R. Bennink, and J.W. Yewdell. 2015. CXCR3 chemokine receptor enables local CD8+ T cell migration for the destruction of virus-infected cells. Immunity 42(3): 524–537.CrossRefPubMedPubMedCentral
17.
Hodge, D.L., W.B. Schill, J.M. Wang, I. Blanca, D.A. Reynolds, J.R. Ortaldo, and H.A. Young. 2002. IL-2 and IL-12 alter NK cell responsiveness to IFN-γ-inducible protein 10 by down-regulating CXCR3 expression. The Journal of Immunology 168(12): 6090–6098.CrossRefPubMed
18.
Panzer, U., R.R. Reinking, O.M. Steinmetz, G. Zahner, U. Sudbeck, S. Fehr, B. Pfalzer, A. Schneider, F. Thaiss, M. Mack, S. Conrad, H. Huland, U. Helmchen, and R.A. Stahl. 2004. CXCR3 and CCR5 positive T-cell recruitment in acute human renal allograft rejection. Transplantation 78(9): 1341–1350.CrossRefPubMed
19.
Tatapudi, R.R., T. Muthukumar, D. Dadhania, R. Ding, B. Li, V.K. Sharma, E. Lozada-Pastorio, N. Seetharamu, C. Hartono, D. Serur, S.V. Seshan, S. Kapur, W.W. Hancock, and M. Suthanthiran. 2004. Noninvasive detection of renal allograft inflammation by measurements of mRNA for IP-10 and CXCR3 in urine. Kidney International 65(6): 2390–2397. doi:10.​1111/​j.​1523-1755.​2004.​00663.​x.CrossRefPubMed
20.
Lazzeri, E., M. Rotondi, B. Mazzinghi, L. Lasagni, A. Buonamano, A. Rosati, F. Pradella, V. Fossombroni, G. La Villa, M. Gacci, E. Bertoni, M. Serio, M. Salvadori, and P. Romagnani. 2005. High CXCL10 expression in rejected kidneys and predictive role of pretransplant serum CXCL10 for acute rejection and chronic allograft nephropathy. Transplantation 79(9): 1215–1220.CrossRefPubMed
21.
22.
Schmittgen, T.D., and K.J. Livak. 2008. Analyzing real-time PCR data by the comparative CT method. Nature Protocols 3(6): 1101–1108.CrossRefPubMed
23.
Ramos, E., C., Drachenberg, M., Portocarrero, R.,Wali, D., Klassen, J., Fink, A., Farney, Hirsch, Papadimitriou, H.J., and C. Cangro. 2001. BK virus nephropathy diagnosis and treatment: experience at the University of Maryland Renal Transplant Program. Clinical Transplants:143–153.
24.
Zare-Bidaki, M., M. Karimi-Googheri, G. Hassanshahi, N. Zainodini, and M.K. Arababadi. 2015. The frequency of CCR5 promoter polymorphisms and CCR5 Delta 32 mutation in Iranian populations. Iran Journal of Basic Medicine Science 18(4): 312–316.
25.
Lin, Q., Y. Song, X. Zhu, S. Yang, and J. Zheng. 2013. Expressions of CXCL9, CXCL10 and CXCL11 in renal tubular epithelial cells induced by IFN-gamma. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 29(2): 137–140.PubMed
26.
Kakuta, Y., M. Okumi, S. Miyagawa, K. Tsutahara, T. Abe, K. Yazawa, K. Matsunami, H. Otsuka, S. Takahara, and N. Nonomura. 2012. Blocking of CCR5 and CXCR3 suppresses the infiltration of macrophages in acute renal allograft rejection. Transplantation 93(1): 24–31. doi:10.​1097/​TP.​0b013e31823aa585​.CrossRefPubMed
27.
Segerer, S., G.A. Böhmig, M. Exner, D. Kerjaschki, H. Regele, and D. Schlöndorff. 2005. Role of CXCR3 in cellular but not humoral renal allograft rejection. Transplant International 18(6): 676–680.CrossRefPubMed
28.
Inston, N., M. Drayson, A. Ready, and P. Cockwell. 2007. Serial changes in the expression of CXCR3 and CCR5 on peripheral blood lymphocytes following human renal transplantation. Experimental and Clinical Transplantation 5(2): 638–642.PubMed
29.
Akalin, E., S. Dikman, B. Murphy, J.S. Bromberg, and W.W. Hancock. 2003. Glomerular infiltration by CXCR3+ ICOS+ activated T cells in chronic allograft nephropathy with transplant glomerulopathy. American Journal of Transplantation 3(9): 1116–1120.CrossRefPubMed
30.
Kariminik, A., R. Yaghoobi, and S. Dabiri. 2016. CXCL9 expression and polyomavirus BK infectivity in renal transplant patients with nephropathy. Cellular and Molecular Biology 62(1): 104–8.PubMed
Metadata
Title
Polyomavirus BK Induces Inflammation via Up-regulation of CXCL10 at Translation Levels in Renal Transplant Patients with Nephropathy
Authors
Ashraf Kariminik
Shahriar Dabiri
Ramin Yaghobi
Publication date
01-08-2016
Publisher
Springer US
Published in
Inflammation / Issue 4/2016
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-016-0385-4

Other articles of this Issue 4/2016

Inflammation 4/2016 Go to the issue

ORIGINAL ARTICLE

The Effects of Rifampin, Povidone-Iodine and Hydrogen Peroxide on the Formation of Epidural Fibrosis in the Experimental Epidural Fibrosis Model

ORIGINAL ARTICLE

Pharmacological Beta-Adrenergic Receptor Activation Attenuates Neutrophil Recruitment by a Mechanism Dependent on Nicotinic Receptor and the Spleen

ORIGINAL ARTICLE

Effect of Low-Power Laser (LPL) and Light-Emitting Diode (LED) on Inflammatory Response in Burn Wound Healing

ORIGINAL ARTICLE

Statins and IL-1β, IL-10, and MPO Levels in Gingival Crevicular Fluid: Preliminary Results

ORIGINAL ARTICLE

Anti-Inflammation Effects and Potential Mechanism of Saikosaponins by Regulating Nicotinate and Nicotinamide Metabolism and Arachidonic Acid Metabolism

ORIGINAL ARTICLE

Isorhamnetin ameliorates LPS-induced inflammatory response through downregulation of NF-κB signaling
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits